Silence Therapeutics Plc American Depository Share (SLN) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Silence Therapeutics Plc American Depository Share (NASDAQ: SLN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $19.76 (+0.05% 1D, market cap $1.23B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SLN ranks #384 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SLN carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 61.5%, and ROIC of -35.0%. By comparison, SNDX (Syndax Pharmaceuticals Inc.) holds a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $1.22B) and OPK (OPKO Health Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -10.2%, cap $1.24B). Among the 5-stock peer group, SLN leads on earnings multiple (N/A) while OPK leads on capital efficiency (-10.2% ROIC).
Per SLN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001479615), Silence Therapeutics Plc American Depository Share generated $559.0K in revenue (-98.7% YoY), -$88.6M in net income, and -$62.3M in free cash flow against $131.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±6.9% realized swing band)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 34.4% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While SLN currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Big institutional funds and options desks are actively positioning on the bullish side.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.74) and Max Pain ($20.75) forces dealer call-delta covering toward $21.85.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Silence Therapeutics Plc American Depository Share (SLN) advanced +0.05% to $19.76, trading at 99% of its 52-week range ($4.19 – $19.86). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
HC Wainwright & Co. analyst Patrick R. Trucchio downgrades Silence Therapeutics (NASDAQ:SLN) from Buy to Neutral and lowers the price target from $75 to $20.
Nasdaq unusual volume movers include NWGL, WORX, HUIZ, HODO and SHFS, with trading volumes well above 50-day averages and a mix of sharp gains and declines.
Market Updates News Commentary - Two unrelated announcements on Monday put one of biotech's smaller corners in the spotlight. A company developing a treatment for a rare light-sensitivity disorder reported that its pivot
The consensus price target hints at an 82.8% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisio
Market sentiment improved slightly but stayed in extreme fear. Nasdaq rose 1.11%, while Silence Therapeutics surged 126% on Merck deal.
Silence Therapeutics has surged into the spotlight after a sharp re-rating of its share price and a takeover agreement, which puts fresh focus on a simple question for investors. With the stock now trading near the agree
Silence Therapeutics (NASDAQ:SLN) kicked off the trading week by more than doubling its share price, as investors snapped up its shares following Merck KGaA’s offer to acquire the company for a 130-percent premium. In se
Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.
Today's top US movers include sharp double-digit swings in small-cap stocks, led by SLN and WORX among gainers and NWGL and CLRO among losers.
Merck KGaA is to buy Silence Therapeutics plc for $1.3B cash at $20/ADS (130% premium). Click for a look at SLN and see why I am downgrading it.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -98.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SLN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SLN. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Silence Therapeutics Plc American Depository Share (SLN) ranks #384 by composite RQD confidence (44/100, grade D) and #329 by equity capitalization ($1.23B). Within this direct 5-issuer industry benchmark cohort, SLN leads on earnings valuation at N/A trailing P/E, while OPK leads on capital efficiency and profitability with -10.2% ROIC and 33.9% gross margin. SLN currently leads its immediate peer cohort in composite quantitative strength at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SLN
ACTIVE
Silence Therapeutics Plc American Depository Share | D | 44/100 | — | 61.5% | -35.0% | +0.05% | $1.23B | Benchmark Subject |
| SNDX Syndax Pharmaceuticals Inc. | E | 17/100 | — | — | -35.0% | -4.03% | $1.22B | /sndx-vs-sln → |
| OPK OPKO Health Inc. | D- | 40/100 | — | 33.9% | -10.2% | +3.61% | $1.24B | /opk-vs-sln → |
| RAPP Rapport Therapeutics Inc. | E | 30/100 | — | — | -22.9% | +0.32% | $1.20B | /rapp-vs-sln → |
| VSTM Verastem Inc. | D- | 36/100 | — | — | -35.0% | -1.64% | $1.18B | /vstm-vs-sln → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Silence Therapeutics Plc American Depository Share (SLN) reported GAAP revenue of $559.0K (-98.7% vs. FY2024 revenue of $43.3M , and -98.2% cumulative change since FY2023) , GAAP net income of -$88.6M, operating cash flow of -$62.3M, and free cash flow of -$62.3M (+8.1% YoY). On the balance sheet, SLN closed FY2025 with $131.4M in total assets against $0 in total debt (Altman Z-Score: 3.36, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $559.0K | -$88.6M | -$62.3M | -$62.3M | $131.4M | — |
| FY2024 (FY) | 2024-12-31 | $43.3M | -$45.3M | -$67.6M | -$67.9M | $202.6M | — |
| FY2023 (FY) | 2023-12-31 | $31.6M | -$54.2M | -$49.5M | -$49.5M | — | — |
As of 2026-11-03, Silence Therapeutics Plc American Depository Share (NASDAQ: SLN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $19.76 (+0.05% 1D, market cap $1.23B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SLN ranks #384 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SLN carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 61.5%, and ROIC of -35.0%. By comparison, SNDX (Syndax Pharmaceuticals Inc.) holds a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $1.22B) and OPK (OPKO Health Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -10.2%, cap $1.24B). Among the 5-stock peer group, SLN leads on earnings multiple (N/A) while OPK leads on capital efficiency (-10.2% ROIC).
Per SLN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001479615), Silence Therapeutics Plc American Depository Share generated $559.0K in revenue (-98.7% YoY), -$88.6M in net income, and -$62.3M in free cash flow against $131.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
SLN last traded at $19.76 (+0.05% on volume of 1,186,323 shares), positioning the stock +43.81% above its 50-day simple moving average ($13.74) and +114.78% above its 200-day simple moving average ($9.20). Across its 52-week range of $4.19 to $19.86, SLN sits at the 99.4% percentile with a 14-day RSI of 78.5 (OVERBOUGHT (>70)) and an implied next-earnings move of ±6.9% ($18.40 to $21.12).
Silence Therapeutics Plc American Depository Share (SLN) earns a live Roarable RQD composite score of 44/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $19.76 (+0.05% 1D, market capitalization $1.23B).
. Its market capitalization is $1.2B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Silence Therapeutics Plc American Depository Share (SLN) reported $559.0K in annual revenue (up from $43.3M in FY2024, -98.7% YoY) and -$88.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($31.6M revenue, -$54.2M net income) through FY2025, SLN scaled operating cash flow to -$62.3M and free cash flow to -$62.3M, backed by $131.4M in total assets against $0 in total debt.
Sector is Health Care and industry is Biotechnology: Pharmaceutical Preparations.
Real-time company headlines, analyst actions, and sector developments for Silence Therapeutics Plc American Depository Share (SLN) • Click "Debate This Headline" to argue it in the Roar Pit below
HC Wainwright & Co. analyst Patrick R. Trucchio downgrades Silence Therapeutics (NASDAQ:SLN) from Buy to Neutral and lowers the price target from $75 to $20.
Nasdaq unusual volume movers include NWGL, WORX, HUIZ, HODO and SHFS, with trading volumes well above 50-day averages and a mix of sharp gains and declines.
Market Updates News Commentary - Two unrelated announcements on Monday put one of biotech's smaller corners in the spotlight. A company developing a treatment for a rare light-sensitivity disorder reported that its pivot
The consensus price target hints at an 82.8% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisio
Market sentiment improved slightly but stayed in extreme fear. Nasdaq rose 1.11%, while Silence Therapeutics surged 126% on Merck deal.
Silence Therapeutics has surged into the spotlight after a sharp re-rating of its share price and a takeover agreement, which puts fresh focus on a simple question for investors. With the stock now trading near the agree
Silence Therapeutics (NASDAQ:SLN) kicked off the trading week by more than doubling its share price, as investors snapped up its shares following Merck KGaA’s offer to acquire the company for a 130-percent premium. In se
Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.
Here is why I am bullish on SLN here at $19.75: Institutional accumulation and options positioning earn the highest RQD pillar score (16/20), indicating relative strength in whale-flow signals.. Compare SLN's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $18.76 are getting bought.
@SkepticalCFA Shorting a 16/20 institutional whale-flow stock at $19.75 is dangerous when funds are rotating into Health Care.
A -35% ROIC, -5.06% FCF yield, and an FY 2025 cash balance of $11.3M against -$62.3M free cash flow point to weak cash generation and limited runway.. Look at the math on SLN: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $17.38 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: